文献速递慢性肾脏病水电解质与酸碱

别嘌醇、非布司他与苯溴马隆对高尿酸血症CKD患者肾功能疗效比较

Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究基于台湾长期整合性CKD照护项目的药流行病学队列,纳入874例新使用别嘌醇、非布司他或苯溴马隆的高尿酸血症CKD患者,比较三种药物对透析进展风险及血尿酸变化的影响。结果显示,与别嘌醇相比,苯溴马隆与透析进展风险降低相关(aHR 0.50,95%CI 0.25-0.99),非布司他与别嘌醇的ESRD风险相当(aHR 0.99,95%CI 0.40-2.44);非布司他降尿酸作用最强。

要点

  • 苯溴马隆较别嘌醇降低透析进展风险(aHR 0.50,95%CI 0.25-0.99)。
  • 非布司他与别嘌醇的ESRD风险相当(aHR 0.99,95%CI 0.40-2.44)。
  • 非布司他降血尿酸作用显著强于别嘌醇或苯溴马隆。

核心结论

  • 在CKD高尿酸血症患者中,与别嘌醇相比,非布司他和苯溴马隆可能更有效降低透析进展风险及血尿酸水平。

研究设计与样本

  • 药流行病学队列研究,纳入台湾长期整合性CKD照护项目中874例新使用别嘌醇、非布司他或苯溴马隆的高尿酸血症患者。
  • 采用多重倾向评分校正的Cox比例风险模型分析。

主要发现

  • 与别嘌醇相比,苯溴马隆治疗与透析进展风险降低相关,校正风险比为0.50(95%CI 0.25-0.99)。
  • 接受别嘌醇或非布司他的患者ESRD风险相当,校正风险比为0.99(95%CI 0.40-2.44)。
  • 在完全校正模型中,非布司他降低血尿酸水平显著强于别嘌醇或苯溴马隆。
  • 在达到治疗目标的患者中,起始非布司他或苯溴马隆者的ESRD风险显著更低。

关键数值与推荐

  • 主要结局为终末期肾病(ESRD)发生率,次要结局为血尿酸较基线变化。
  • 亚组分析根据最新血尿酸水平是否达到治疗目标进行分层。

临床怎么用

  • 在CKD高尿酸血症患者选择降尿酸药物时,可考虑苯溴马隆或非布司他作为别嘌醇的替代,以可能降低透析进展风险。
  • 非布司他降尿酸作用更强,但需结合患者个体情况选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct comparisons of the effectiveness of allopurinol with that of other urate-lowering agents in chronic kidney disease (CKD) populations, as well as guideline recommendations for clinical practice, are lacking. METHODS: We constructed a pharmacoepidemiology cohort study by including patients from Taiwan's long-term integrated CKD care program to compare the effectiveness among allopurinol, febuxostat and benzbromarone in reducing the risk of progression to dialysis. A total of 874 patients with hyperuricemia who were newly treated with allopurinol, febuxostat or benzbromarone were included. The primary and secondary outcomes were incident end-stage renal disease (ESRD) and the serum uric acid (SUA) changes from baseline, respectively. The results were analyzed using multiple Cox proportional models adjusted for multinomial propensity scores. For subgroup analyses, we further stratified patients according to whether their latest SUA level reached the therapeutic target. RESULTS: Compared with allopurinol, benzbromarone therapy was associated with a reduced risk of progression to dialysis, the adjusted hazard ratio was 0.50 (95% confidence interval, 0.25-0.99). Patients who received allopurinol or febuxostat exhibited a comparable risk of ESRD [adjusted hazard ratio, 0.99 (0.40-2.44)]. Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model. Among patients who reached the therapeutic target, those with febuxostat and benzbromarone initiation had a significantly lower risk of ESRD. CONCLUSIONS: In conclusion, compared with conventional allopurinol, febuxostat and benzbromarone may be more effective in reducing the risk of progression to dialysis and in lowering SUA levels in CKD populations.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018. PMID: 29165620. doi:10.1093/ndt/gfx313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。